Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05321407 · ClinicalTrials.gov registry record

COVID-19 Vaccine Responses in PIDD Subjects

A clinical trial of Common Variable Immunodeficiency and Primary Immune Deficiency, sponsored by Duke University.

Active
Registry status
100
Enrollment target
3
Study locations

NCT05321407: Active study of Common Variable Immunodeficiency and Primary Immune Deficiency, sponsored by Duke University.

NCT05321407 is a study of Common Variable Immunodeficiency and Primary Immune Deficiency that is active but no longer recruiting, run by Duke University. The registered enrollment target is 100 participants, below the 215-participant average among 7 other Common Variable Immunodeficiency trials with a reported enrollment target (53% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05321407, a study of Common Variable Immunodeficiency and Primary Immune Deficiency, is active but no longer recruiting, sponsored by Duke University.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
3
Study locations

Study Summary

The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.

Study Locations (3)

North Carolina

  • University of North Carolina, Chapel Hill - Chapel Hill
  • Duke University - Durham

Florida

  • University of South Florida - St. Petersburg

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-09-30
Est. Completion 2026-07-31
Duke University

1,725 total trials

What the registry record for NCT05321407 still lists

NCT05321407 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 215-participant average among 7 other Common Variable Immunodeficiency trials with a reported enrollment target (53% lower).

The record links to 7 conditions, with Common Variable Immunodeficiency appearing as the primary indexed condition, and to 0 interventions.

NCT05321407 reports a single indexed study location in North Carolina, Florida.

Frequently Asked Questions

What is clinical trial NCT05321407 about?

NCT05321407 is a clinical study titled "COVID-19 Vaccine Responses in PIDD Subjects". The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.

What is the current status of trial NCT05321407?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2021-09-30. Estimated completion is 2026-07-31.

What conditions does trial NCT05321407 study?

This clinical trial studies the following conditions: Common Variable Immunodeficiency, Primary Immune Deficiency, CVID, XLA, X-linked Agammaglobulinemia.

Who is sponsoring clinical trial NCT05321407?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05321407 being conducted?

This trial has 3 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Common Variable Immunodeficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05321407, the US trial registry maintained by the National Library of Medicine. NCT05321407 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.